Compositions and methods for the treatment and diagnosis of eosinophilic esophagitis are disclosed.

The present invention relates to a method for the detection of lactose tolerance markers in a sample by lateral flow immunoassay, a lateral flow immunoassay device, primers and extraction buffer and uses thereof and related tools and assays useful in said method.

The disclosure relates to the field of the human gut microbiome, more particularly, to its effect on health and disease. Provided herein are means and methods to diagnose and treat or reduce the severity of gut flora dysbiosis as well as of gastro-intestinal inflammation and inflammation-associated disorders or conditions in a subject in need thereof.

The invention relates to methods and kits for diagnosing and/or treating appendicitis in a subject, comprising performing one or more assays configured to detect one or more biomarkers on a body fluid sample obtained from the subject to provide one or more assay result(s) and correlating the assay result(s) to the occurrence or nonoccurrence of appendicitis in the subject or likelihood of the future outcome to the subject.

The invention provides antibodies that specifically bind to an epitope containing N-acetylglucosamine or N-acetyl-galactosamine expressed by a cancer cell or an inflammatory cell. Also provided are compositions including these antibodies, as well as polynucleotides, vectors, host cells, and methods useful for production thereof. Further provided are methods and kits for treating or preventing cancer in an individual by administering to the individual an antibody that specifically binds to an epitope containing N-acetylglucosamine or N-acetyl-galactosamine, optionally in combination with another anti-cancer agent. Still further provided are methods and kits for treating or preventing gastrointestinal disease in an individual by administering to the individual an antibody that specifically binds to an epitope containing N-acetylglucosamine or N-acetyl-galactosamine. Yet further provided are methods and kits for detecting the presence of cancer cells in an individual including an antibody that specifically binds to an epitope containing N-acetylglucosamine and/or N-acetyl-galactosamine.

The present invention relates to the field of mucin isoforms, more in particular for use in the diagnosis, monitoring, prevention and/or treatment of a disease characterized by barrier dysfunction, such as but not limited to a gastrointestinal disorder (e.g. Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), cancer, gastro-intestinal infections, obesitas, non-alcoholic fatty liver disease (NAFLD)), neurodegenerative disorders, respiratory infections, . . . In a specific embodiment, said mucin isoform is selected from the list comprising: MUC1 isoforms and MUC13 isoforms.

In some embodiments, a method for aiding prediction of the likelihood of progression from Barrett's esophagus to high grade dysplasia or esophageal adenocarcinoma in a subject, is disclosed. The method can include (a) providing an oesophagal sample from said subject (b) determining if said sample stains abnormally with Aspergillus oryzae lectin; (c) determining if there is a DNA content abnormality in said sample; and (d) determining if there is low grade dysplasia in said sample; wherein if (b) is abnormal and (c) is abnormal and low grade dysplasia is present, then an increased likelihood of progression is determined. The disclosed subject matter also relates to an apparatus, and to different uses of certain materials.

Methods for the diagnosis of CRC, colorectal polyps in general and adenomatous polyps in particular by measurement of metabolites in urine are described. In some embodiments, certain metabolites are identified as being elevated or reduced in concentration or quantity in subjects with CRC and/or colorectal polyps as compared with subjects without CRC or colorectal polyps. The measurement of these metabolites in urine can indicate the presence of CRC or colorectal polyps in general or adanomatous polyps in particular in a subject.

A recombinant deamidated gliadin polypeptide antigen, a recombinant antigen-expressing gene, a recombinant expression vector, a preparation method therefor, and an application thereof. The recombinant deamidated gliadin polypeptide antigen comprises a DGP-1 peptide, an interleukin 15 protein, and a DGP-2 peptide. The amino acid sequence of the DGP-1 peptide is as shown in SEQ ID NO. 1, and the amino acid sequence of the DGP-2 peptide is as shown in SEQ ID NO 2. The recombinant deamidated gliadin polypeptide antigen has good sensitivity, high specificity, and low preparation costs in the detection of celiac disease, allows determination of IgG-DGP antibodies in serum, and especially enables diagnosis for potential patients with celiac disease among patients with IgA deficiency and infant population.

The invention provides a compound characterized by formula (1): X1-Thr-Thr-Ala-Arg-X2, wherein cleavage of the compound into a fragment 1 comprising X1 and a fragment 2 comprising X2 generates a detectable signal. The invention further provides an in vitro method for detecting protease activity in a subject's body fluid, comprising contacting the body fluid with the compound of the invention and detecting a signal, wherein the body fluid may comprise a hydrolytic enzyme derived from pancreatic cancer cells. Furthermore, the invention provides a kit comprising the compound of the invention and a measurement buffer. In addition, the invention provides the use of the compound, the in vitro method or the kit of the invention for the detection of pancreatic cancer, or for monitoring a subject that is suspected of having pancreatic cancer, has an increased risk of developing pancreatic cancer, or has had pancreatic cancer. The invention also provides the use of the compound of the invention in a method of treating pancreatic cancer, the method comprising carrying out the in vitro method for detecting protease activity in a subject's body fluid, and treating pancreatic cancer in a subject for which protease activity, has been detected.